

AMENDMENTS TO THE CLAIMS

Please cancel claims ~~1-36~~ 1-27 without prejudice. Please add new claims ~~37-45~~ 28-36, as indicated below.

~~1-36~~ 1-27. (Canceled).

~~37~~ 28. (Currently Amended) An oligonucleotide, comprising: 5'-TGACGTT-3', 5'TGACGTC3' or 5'-AACGTT-3', 8-40 nucleotides in length, and having at least one phosphate backbone modification.

~~38~~ 29. (Currently Amended) The oligonucleotide of claim ~~37~~ 28, wherein the oligonucleotide is linked to a nucleic acid delivery complex.

~~39~~ 30. (Currently Amended) The oligonucleotide of claim ~~38~~ 29, wherein the oligonucleotide is ionically linked to or encapsulated in the nucleic acid delivery complex.

~~40~~ 31. (Currently Amended) The oligonucleotide of claim ~~38~~ 29, wherein the oligonucleotide is covalently linked to the nucleic acid delivery complex.

~~41~~ 32. (Currently Amended) The oligonucleotide of claim ~~38~~ 29, wherein the nucleic acid delivery complex is a cationic lipid.

~~42~~ 33. (Currently Amended) The oligonucleotide of claim ~~38~~ 29, wherein the nucleic acid delivery complex is a sterol.

~~43~~ 34. (Currently Amended) The oligonucleotide of claim ~~37~~ 28, wherein the oligonucleotide comprises 5'-TCAACGTT-3'

44 35. (Currently Amended) The oligonucleotide of claim 42 33, wherein the phosphate backbone modification is a phosphorothioate.

45 36. (Currently Amended) A composition comprising the oligonucleotide of claim 37 28 and a pharmaceutically acceptable carrier.